by University of North Carolina at Chapel Hill School of Medicine EIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dementia (LBD) demonstrated an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily demonstrated significant...
